A clinical trial of CAR-T therapies has brought the word curable almost within touching distance for multiple myeloma, the second most common blood cancer in the world, thus increasing hope and qualit...
Una investigación de la Universidad de Granada ha identificado nuevas mutaciones relacionadas con el linfoma que ayudan a entender mejor cómo se producen estos tumores
OneChain Immunotherapeutics (OCI), a biotechnology company specializing in the development of CAR T cell therapies for oncological diseases, announced today the first patient dosed in the CARxALL clin...
More specifically, it demonstrates how the affinity of the CAR T-cell to the tumour receptor modulates both its efficacy and resistance to the suppressive mechanisms of solid tumours.